The Mission

Combine AI and Biomedical science for medication development.

Problem

Multiple Sclerosis (MS) remains a challenging disease to treat effectively, with existing therapies limited to symptom management or slowing disease progression. There is a significant unmet need for innovative treatments targeting the underlying mechanisms of MS to improve patients' quality of life. At the end, we aim to innovative treatment for not only MS but also other disciplinary of illnesses.

The Solution

Our solution involves developing monoclonal antibodies to act as agonists for Siglec-10, a membrane protein involved in immune modulation. By activating Siglec-10 signaling pathways, the treatment aims to reduce neuroinflammation and protect myelin sheaths from immune-mediated damage, offering a novel therapeutic approach for MS patients.